Cellectis S.A. (CLLS)
NASDAQ: CLLS · IEX Real-Time Price · USD
2.060
+0.030 (1.48%)
Jul 22, 2024, 9:30 AM EDT - Market open
Cellectis Employees
As of December 31, 2023, Cellectis had 221 total employees, including 216 full-time and 5 part-time employees. The number of employees decreased by 16 or -6.75% compared to the previous year.
Employees
221
Change (1Y)
-16
Growth (1Y)
-6.75%
Revenue / Employee
$54,896
Profits / Employee
-$295,665
Market Cap
148.51M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Amylyx Pharmaceuticals | 384 |
Electromed | 170 |
Inventiva | 123 |
EUDA Health Holdings | 106 |
Invivyd | 95 |
Vigil Neuroscience | 69 |
Corvus Pharmaceuticals | 28 |
PDS Biotechnology | 25 |
CLLS News
- 23 days ago - Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 - GlobeNewsWire
- 4 weeks ago - Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing - GlobeNewsWire
- 5 weeks ago - Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications - GlobeNewsWire
- 6 weeks ago - Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia - GlobeNewsWire
- 7 weeks ago - Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024 - GlobeNewsWire
- 7 weeks ago - Cellectis Reports Financial Results for First Quarter 2024 - GlobeNewsWire
- 7 weeks ago - Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 - GlobeNewsWire
- 2 months ago - Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca - GlobeNewsWire